by Dave Moenning | September 19, 2013 12:01 pm
At StateoftheMarkets.com, we strive to “own the best and ignore the rest” in our equity portfolios. Toward this end, each day we search our database for a “top stock” (a top rated company in terms of earnings strength as well as company and industry performance) that presents a strong technical “set up” and a good entry point.
In short, when our equity team is looking to add a stock to one of our portfolios, the “bull’s eye” stock shown below is generally their first choice.
|Company||Symbol||Industry||Stock Rating||YTD% Gain||S.T. Stop Loss|
|PAREXEL Intl.||PRXL||Personal Products||9.7||+69.78%||$48.19|
PAREXEL Intl. (PRXL) is our most compelling buy today due to the fact that it is a top-rated stock (in terms of earnings strength and company/industry performance) with a strong technical set-up. Life sciences stocks have been a mixed bag this year. Some larger-cap companies like Pfizer (PFE) and Merck (MRK) have been lagging, while smaller-cap companies like Covance (CVD), WuXi PharmaTech (WX), and PRXL have been superb.
In early August, PRXL hit as high as $51.33 before pulling back and basing just above $46 through late August to early September. Currently, the stock is back on the upswing, crossing above its 50-day moving average last week. PRXL hasn’t pulled back a whole lot this year, so we would jump on the stock while prices are still attractive. We’d be buyers here, and look for a run to new highs north of $52.
At the current price (~$49.87).
PAREXEL International Corporation (PAREXEL) is a biopharmaceutical services company, providing a range of expertise in clinical research, medical communications, consulting, and advanced technology products and services to the worldwide pharmaceutical, biotechnology, and medical device industries. It operates in three segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS) and Perceptive Informatics, Inc. (Perceptive). The company’s product and service offerings include clinical trials management, observational studies and patient/disease registries, data management, biostatistical analysis, epidemiology, health economics / outcomes research, pharmacovigilance, medical communications, clinical pharmacology, patient recruitment, post-marketing surveillance. In May 2013, PAREXEL International Corp acquired the entire share capital of HERON Group Ltd.
The Stock Rating indicates the combined score of our proprietary Earning Strength and Company Performance models. The rating scale is 0 – 10 with 10 being the highest.
Looking to trade the Bull’s Eye stock picks? Click here to download our free Special Report, “How We Identify Our “Bull’s Eye” Picks & How You Can Profit Trading Them”
At the time of publication the editor and affiliated companies own the following positions: None
Note: Positions may be bought or sold while this publication is in circulation without notice.
Source URL: http://investorplace.com/2013/09/bulls-eye-report/
Short URL: http://invstplc.com/1fryz9B
Copyright ©2014 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.